Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials - The Lancet Oncology thelancet.com/journals/lanon…

>70% of the pts in the chemo-alone arm of KN522 are free from recurrence of TNBC at 5 years Identifying these pts is a critical challenge, to avoid exposure to potentially permanent/ life-threatening IO tox Potential tools: TILs, gene-sign, ctDNA, dynamic imaging, among others

Congrats Hatem Fedro Peccatori MD, PhD Ann Partridge MD, MPH et al for reporting in Journal of Clinical Oncology the data presented at #SABCS23 on safety of fertility techniques in patients with #BreastCancer included in #POSITIVE trial..so important results! OncoAlert #bcsm ETOP IBCSG Partners Foundation Link: ascopubs.org/doi/abs/10.120…

Superb discussion within our Cancer and Aging Research Group (CARG) #GeriOnc core call on dissemination of evidence-based care of older adults with #cancer. Check out our recently released ASCO Guideline Update -- honored to be a small part of this effort published in Journal of Clinical Oncology on the Practical Assessment and

More surgery is not better - tailoring to response and EOD spares unnecessary toxicity. OncoAlert

Just published! MASCC Antiemetic Consensus Recommendations: Resource-Limited Settings link.springer.com/article/10.100… #SuppOnc #GlobOnc OncoAlert Supportive Care in Cancer: Springer Journal Dr Snezana Bosnjak Ana Zilic Prof Vikas Ostwal

MASCC OncoAlert Supportive Care in Cancer: Springer Journal Ana Zilic Prof Vikas Ostwal Grateful to MASCC for recognizing the access-to-antiemetic issue and the need to tailor guidelines for resource limited settings & define alternative regimens when NK1-RAs are not accessible. #CancerCare medicines are not just for cancer #AccessToMedicines #SuppOnc

Read our latest #research on #CINV prevention: MASCC antiemetic consensus recommendations: resource-limited settings, published online with Springer Nature in Supportive Care in Cancer: Springer Journal rdcu.be/d9Fj3 #AccessToMedicines #SuppOnc

The most discussed side effect of T-DXd is ILD. Yet the most frequent ones, and the ones that most often lead to dose reduction of T-DXd, are fatigue & emesis. Now confirmed by PRO. Always remember to use adequate anti-emetic prophylaxis (3-drug regimen) + olanzapine when needed!

Zoledronic acid vs. Denosumab in HR+/HER2- aBC with bone mets + CDK4/6i 🔍PSM/IPTW-adjusted retrospective study 🔹ZA prolonged time to 1st SRE vs. DMAB 🔹No difference in PFS or OS between groups 💥ZA might be preferred in this setting despite prior RCTs favoring DMAB?

The role of cardioprotectives in anthracycline-treated patients 💥In the SAFE trial, ramipril/bisoprolol reduced subclinical cardiotoxicity from ~40% to ~10% in anthracycline-treated BC patients with no baseline cardiac risk. Prevention matters!! esmoopen.com/article/S2059-…

Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO25 Patient population considerations: 1) De novo patients (capped at 50%): these patients are more likely to respond durably and possibly even be cured in

BMI analysis of ASCENT. Overweight/obese pts experienced higher rates of serious AEs (34% vs 18%) with SG and 41% of obese pts required dose reduction (vs 10%). Should we cap the dose of SG for overweight/obese pts, similar to other ADCs (eg EV, Dato-DXd)? esmoopen.com/action/consume…

Overcoming resistance to CDK4/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: Innovative combinations and emerging strategies cancertreatmentreviews.com/article/S0305-…

Pregnancy after breast cancer: latest evidence and practical considerations A grest summary of practical matters👇 journals.sagepub.com/overview-metri…

An excellent guideline on the management of adverse events associated with Dato-DXd👇

In early-stage TNBC patients treated with pembrolizumab + chemotherapy:Neo-Real/GBECAM 0123 🔹 Overall irAE rate: 31% 🔹 G≥3 irAEs: 13.6% 📌 Neoadjuvant phase: • Any irAE: 22.6% • G≥3: 8.4% 📌 Adjuvant phase: • Any irAE: 11.3% • G≥3: 3.2% 💬In KN-522, the 5-y OS

Huge thanks to Balazs Halmos and team for publishing this incredibly important manuscript. If you’re prescribing or starting Dato-DXd, this is a checklist you’ll definitely want to BOOKMARK or even PRINT out! 👇🏽👇🏽 EGFR Resisters OncoAlert Oncology Brothers LungCancerRx 🫁💊

Great retrospective study on post-T-DXd outcomes for HER2+ mBC — congrats Kazuki Nozawa, MD!

mFOLFIRINOX or S-IROX vs Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611) 💥mFOLFIRINOX or S-IROX was not found to be superior to gem+ nab-pac; in fact, gem+nab-paclitaxel showed numerically better outcomes ascopubs.org/doi/10.1200/JC…